The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore’s Health Sciences Authority (HSA) have introduced a new Regulatory Innovation Corridor to provide a coordinated fast-track pathway for developers to engage both regulators concurrently, aiming to accelerate patient access to breakthrough therapies.

• Pathway: Enables early joint advice from MHRA and HSA on clinical development planning and evidence requirements.
• Focus: High-impact areas such as cancer, dementia, obesity, rare diseases and advanced diagnostics, while maintaining safety standards.
• Pilot Use: Flagship Pioneering will be the first to use the corridor, helping refine the framework before broader participation.

This summary is based on a press release published on the Health Sciences Authority (HSA).